| scholarly article | Q13442814 |
| P2093 | author name string | Bernd Groner | |
| Boris Brill | |||
| Natalia Delis | |||
| Corina Borghouts | |||
| Laura Mack | |||
| Astrid Weiss | |||
| P2860 | cites work | Survivin mediates targeting of the chromosomal passenger complex to the centromere and midbody | Q24338808 |
| Direct inhibition of the NOTCH transcription factor complex | Q24634015 | ||
| Ferritin for the clinician | Q24642942 | ||
| The mitotic regulator Survivin binds as a monomer to its functional interactor Borealin | Q27648318 | ||
| Current prospects for RNA interference-based therapies | Q28235733 | ||
| Survivin: key regulator of mitosis and apoptosis and novel target for cancer therapeutics | Q28290655 | ||
| Cancer gene therapy using a survivin mutant adenovirus | Q28360690 | ||
| Genome remodelling in a basal-like breast cancer metastasis and xenograft | Q28395637 | ||
| In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector | Q29547503 | ||
| Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo | Q29616612 | ||
| Principles of cancer therapy: oncogene and non-oncogene addiction | Q29616779 | ||
| Balancing acts: molecular control of mammalian iron metabolism | Q29620380 | ||
| Selection and characterization of large collections of peptide aptamers through optimized yeast two-hybrid procedures | Q33280955 | ||
| Study and selection of in vivo protein interactions by coupling bimolecular fluorescence complementation and flow cytometry. | Q33314548 | ||
| Identification of a small-molecule inhibitor of the interaction between Survivin and Smac/DIABLO. | Q33527675 | ||
| Binding and uptake of H-ferritin are mediated by human transferrin receptor-1. | Q33734849 | ||
| Induction of apoptosis by survivin silencing through siRNA delivery in a human breast cancer cell line | Q33991776 | ||
| Ferritin H induction by histone deacetylase inhibitors | Q34034477 | ||
| Reversing chemoresistance by small molecule inhibition of the translation initiation complex eIF4F | Q34508797 | ||
| Drugs, their targets and the nature and number of drug targets | Q34571023 | ||
| Cell signaling in space and time: where proteins come together and when they're apart | Q34583620 | ||
| The challenge of drugging undruggable targets in cancer: lessons learned from targeting BCL-2 family members | Q34727955 | ||
| Impacting tumor cell-fate by targeting the inhibitor of apoptosis protein survivin | Q34871780 | ||
| Targeting survivin overcomes drug resistance in acute lymphoblastic leukemia | Q35182716 | ||
| Histone deacetylase inhibitor belinostat represses survivin expression through reactivation of transforming growth factor beta (TGFbeta) receptor II leading to cancer cell death | Q35183027 | ||
| Our changing view of the genomic landscape of cancer | Q35368205 | ||
| Survivin and IAP proteins in cell-death mechanisms | Q35414780 | ||
| Cellular regulation and molecular interactions of the ferritins. | Q36390445 | ||
| Survivin, a cancer target with an emerging role in normal adult tissues | Q36491426 | ||
| X-linked inhibitor of apoptosis protein as a therapeutic target | Q37008849 | ||
| Regulation of neuronal ferritin heavy chain, a new player in opiate-induced chemokine dysfunction | Q37149240 | ||
| Cancer cells survive with survivin | Q37185505 | ||
| IAP-targeted therapies for cancer | Q37302745 | ||
| New wirings in the survivin networks | Q37302750 | ||
| Reversing cancer from inside and out: oncogene addiction, cellular senescence, and the angiogenic switch | Q37354200 | ||
| Survivin: a new target for anti-cancer therapy | Q37533048 | ||
| Mitochondrial survivin inhibits apoptosis and promotes tumorigenesis. | Q37574259 | ||
| Dynamic interactions of proteins in complex networks: a more structured view. | Q37588014 | ||
| Exploiting the balance between life and death: targeted cancer therapy and "oncogenic shock". | Q37704646 | ||
| Promises and challenges in developing RNAi as a research tool and therapy | Q37815111 | ||
| Is survivin the potential Achilles' heel of cancer? | Q37894400 | ||
| Bio-inspired, bioengineered and biomimetic drug delivery carriers | Q37896455 | ||
| The intracellular delivery of a recombinant peptide derived from the acidic domain of PIAS3 inhibits STAT3 transactivation and induces tumor cell death | Q39718244 | ||
| Monomeric recombinant peptide aptamers are required for efficient intracellular uptake and target inhibition | Q40006737 | ||
| Gambogic acid, a potent inhibitor of survivin, reverses docetaxel resistance in gastric cancer cells | Q40016776 | ||
| Chemokine CXCL12 induces binding of ferritin heavy chain to the chemokine receptor CXCR4, alters CXCR4 signaling, and induces phosphorylation and nuclear translocation of ferritin heavy chain | Q40216949 | ||
| Induction of melanoma cell apoptosis and inhibition of tumor growth using a cell-permeable Survivin antagonist | Q40279512 | ||
| The druggable genome: an update | Q40362716 | ||
| High-level transduction and gene expression in hematopoietic repopulating cells using a human immunodeficiency [correction of imunodeficiency] virus type 1-based lentiviral vector containing an internal spleen focus forming virus promoter | Q45732758 | ||
| Small interfering RNA targeting survivin sensitizes lung cancer cell with mutant p53 to adriamycin | Q46656725 | ||
| Smac agonists sensitize for Apo2L/TRAIL- or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo | Q48548442 | ||
| Early embryonic lethality of H ferritin gene deletion in mice. | Q52171353 | ||
| Monitoring the interference of protein-protein interactions in vivo by bimolecular fluorescence complementation: the DnaK case. | Q52693279 | ||
| High expression of Survivin, mapped to 17q25, is significantly associated with poor prognostic factors and promotes cell survival in human neuroblastoma | Q63874527 | ||
| Therapeutic targeting of the survivin pathway in cancer: initiation of mitochondrial apoptosis and suppression of tumor-associated angiogenesis | Q64377539 | ||
| N-Terminal Deletion Effects of Human Survivin on Dimerization and Binding to Smac/DIABLO in Vitro | Q82377205 | ||
| P433 | issue | 7 | |
| P921 | main subject | cell growth | Q189159 |
| P304 | page(s) | 1205-1220 | |
| P577 | publication date | 2012-03-18 | |
| P1433 | published in | Journal of Cancer Research and Clinical Oncology | Q2081599 |
| P1476 | title | Survivin inhibition by an interacting recombinant peptide, derived from the human ferritin heavy chain, impedes tumor cell growth | |
| P478 | volume | 138 |
| Q34657717 | Association of survivin splice variants with prognosis and treatment of breast cancer |
| Q38239577 | Biology of ferritin in mammals: an update on iron storage, oxidative damage and neurodegeneration |
| Q42227148 | Dysregulation of the intrinsic apoptotic pathway mediates megakaryocytic hyperplasia in myeloproliferative neoplasms. |
| Q33275528 | Examination of survivin expression in 50 chordoma specimens--A histological and in vitro study |
| Q38395896 | Hypoxic tumor microenvironment in advanced retinoblastoma. |
| Q38028795 | Increasing the range of drug targets: interacting peptides provide leads for the development of oncoprotein inhibitors |
| Q38212609 | Oncoapoptotic markers in oral cancer: prognostics and therapeutic perspective |
| Q49392235 | Survivin regulated by autophagy mediates hyperglycemia-induced vascular endothelial cell dysfunction |
| Q38040407 | Targeting malignant mitochondria with therapeutic peptides. |
| Q27022941 | Targeting oncogenic ALK and MET: a promising therapeutic strategy for glioblastoma |
| Q34954296 | Targeting survivin in cancer: novel drug development approaches |
Search more.